Naprod Life Sciences Renews EU-GMP Certification for its Palghar Facility
Overview
Naprod Life Sciences has announced the successful renewal of its European Union Goods Manufacturing Practices (EU-GMP) certification for its manufacturing facility in Palghar. The approval marks a significant milestone for Naprod in its journey of global leadership. The audit was conducted in December 2023 by The National Institute of Pharmacy and Nutrition (OGYÉI), Hungary.
Words from Naprod Life Sciences
Speaking on the development, Mohan Jain, managing director at Naprod Life Sciences said, “The EU GMP certification for our facility in Palghar is a testament to our consistent efforts to comply with the highest quality standards. We are committed to being compliant and supplying quality products to our customers and patients across the globe.”
EU-GMP Certification
- The EU-GMP certification highlights the Palghar facility’s capabilities to ensure consistent and controlled production in accordance with the EU’s quality standards.
- The facility produces a wide range of formulations, liquid and lyophilised injectable products, with a special focus on oncology, anaesthetics and other therapy segments.
Naprod Life Sciences Pvt. Ltd.
- Naprod Life Sciences Pvt. Ltd. (Naprod) is a leading Indian pharmaceutical company established in 1994, headquartered in Mumbai.
- Naprod has grown to become a global leader in oncology and anaesthesia medications for both the Indian and international markets through excellence in innovation, the discovery of new manufacturing processes, drug delivery mechanisms and a consistent commitment to quality.
Company’s Portfolio
- With over 550 employees, Naprod primarily manufactures and sells formulations and specialty injectables.
- The company’s portfolio includes products for oncology, cardiovascular, anaesthetic, anti-ulcerative and anti-Infective medicines.
- The company has one manufacturing plant in Palghar, Maharashtra. The plant holds accreditations by multiple regulatory authorities including EU GMP, ANVISA Brazil, INVIMA Colombia, PICS, and authorities in Africa and CIS countries.
